• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Denosumab--an emerging treatment for postmenopausal osteoporosis.
【24h】

Denosumab--an emerging treatment for postmenopausal osteoporosis.

机译：地诺单抗-绝经后骨质疏松症的新兴治疗方法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IMPORTANCE OF THE FIELD: Osteoporosis is a common skeletal disease that is associated with an imbalance in bone remodeling. Denosumab is an investigational fully human monoclonal antibody to receptor activator of NF-kappaB ligand (RANKL), a cytokine member of the TNF family that is the principal mediator of osteoclastic bone resorption. AREAS COVERED IN THIS REVIEW: The efficacy and safety of denosumab in the management of postmenopausal osteoporosis is evaluated by reviewing the published literature and presentations at scientific meetings through 2009. WHAT THE READER WILL GAIN: This review focuses on the data on fracture risk reduction and safety endpoints of denosumab in the treatment of postmenopausal osteoporosis. TAKE HOME MESSAGE: In postmenopausal women with osteoporosis, denosumab (60 mg by subcutaneous injection every 6 months) increased bone mineral density, reduced bone turnover markers, and reduced the risk of vertebral, hip and non-vertebral fractures. Denosumab was well tolerated with a safety profile generally similar to placebo. It is a promising emerging drug for the prevention and treatment of postmenopausal osteoporosis.
机译：领域的重要性：骨质疏松症是一种常见的骨骼疾病，与骨骼重塑失衡有关。 Denosumab是针对NF-κB配体（RANKL）的细胞因子成员的NF-κB受体激活剂的研究性全人类单克隆抗体，它是破骨细胞骨吸收的主要介质。这篇综述所涵盖的领域：地诺舒单抗在绝经后骨质疏松症管理中的有效性和安全性，是通过回顾直到2​​009年的科学会议上发表的文献和演讲进行评估的。 denosumab在绝经后骨质疏松症治疗中的安全性终点。寄语：绝经后骨质疏松的妇女中，地诺单抗（每6个月皮下注射60 mg）可增加骨矿物质密度，减少骨转换标志物，并减少椎骨，髋部和非椎骨骨折的风险。地诺单抗的耐受性良好，通常与安慰剂相似。它是预防和治疗绝经后骨质疏松的有前途的新兴药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号